| Endpoints | Group A No Anti-HTN Medication (n=30) | Group B 1 Anti-HTN Medication (n=30) | Group C 2 Anti-HTN Medications (n=56) | Group D ≥ 3 Anti-HTN Medications (n=24) | P-Value |
|---|---|---|---|---|---|
| 3-Year Actuarial Survival | 100.00% | 89.80% | 84.10% | 91.70% | 0.592 |
| 3-Year Actuarial Freedom from CAV | 88.20% | 95.80% | 80.20% | 79.30% | 0.261 |
| 3-Year Actuarial Freedom from NF-MACE | 100.00% | 96.70% | 86.80% | 100.00% | 0.067 |
| 1-Year Actual Freedom from Any Treated Rejection | 93.30% | 90.00% | 77.60% | 86.20% | 0.398 |
| 1-Year Actual Freedom from Antibody Mediated Rejection | 96.70% | 93.30% | 96.40% | 100.00% | 0.631 |
| 1-Year Actual Freedom from Acute Cellular Rejection | 93.30% | 96.70% | 86.80% | 91.00% | 0.636 |
| 1-Year Actual Freedom from Biopsy Negative Rejection | 100.00% | 100.00% | 90.70% | 95.20% | 0.194 |
| Interventricular Septal Thickness (IVS) > 1.2 cm | 10.0% (3/30) | 13.3% (4/30) | 16.1% (9/56) | 16.7% (4/24) | P=NS |
| Left Ventricular Posterior Wall (LVPW) > 1.2 cm | 3.3% (1/30) | 6.7% (2/30) | 7.1% (4/56) | 8.3% (2/24) | P=NS |
P=NS.